Interojo Inc. (KOSDAQ:119610)
19,970
+120 (0.60%)
Apr 10, 2026, 3:30 PM KST
Interojo Revenue
In the year 2025, Interojo had annual revenue of 118.44B KRW with 2.24% growth. Interojo had revenue of 31.62B in the quarter ending December 31, 2025, with 40.77% growth.
Revenue
118.44B
Revenue Growth
+2.24%
P/S Ratio
1.92
Revenue / Employee
172.40M
Employees
687
Market Cap
227.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.44B | 2.60B | 2.24% |
| Dec 31, 2024 | 115.84B | -3.46B | -2.90% |
| Dec 31, 2023 | 119.30B | 1.48B | 1.25% |
| Dec 31, 2022 | 117.82B | 10.29B | 9.57% |
| Dec 31, 2021 | 107.53B | 19.33B | 21.92% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Samsung Epis Holdings | 3.02T |
| Chong Kun Dang Holdings | 959.01B |
| Samjin Pharmaceuticals | 274.03B |
| Ilyang Pharmaceutical Co.,Ltd | 272.42B |
| Vieworks | 239.33B |
| ALTEOGEN | 215.86B |